JP2024505562A - 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法 - Google Patents
選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法 Download PDFInfo
- Publication number
- JP2024505562A JP2024505562A JP2023546439A JP2023546439A JP2024505562A JP 2024505562 A JP2024505562 A JP 2024505562A JP 2023546439 A JP2023546439 A JP 2023546439A JP 2023546439 A JP2023546439 A JP 2023546439A JP 2024505562 A JP2024505562 A JP 2024505562A
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkylene
- branched
- alkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163144577P | 2021-02-02 | 2021-02-02 | |
| US63/144,577 | 2021-02-02 | ||
| PCT/US2022/014790 WO2022169780A1 (en) | 2021-02-02 | 2022-02-01 | Selective bcl-xl protac compounds and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024505562A true JP2024505562A (ja) | 2024-02-06 |
| JP2024505562A5 JP2024505562A5 (https=) | 2025-02-07 |
Family
ID=80735817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023546439A Pending JP2024505562A (ja) | 2021-02-02 | 2022-02-01 | 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20240376094A2 (https=) |
| EP (1) | EP4288434A1 (https=) |
| JP (1) | JP2024505562A (https=) |
| KR (1) | KR20230170644A (https=) |
| CN (1) | CN117794929A (https=) |
| AU (1) | AU2022218128A1 (https=) |
| CA (1) | CA3206906A1 (https=) |
| IL (1) | IL304891A (https=) |
| WO (1) | WO2022169780A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230171979A (ko) | 2021-04-16 | 2023-12-21 | 아비나스 오퍼레이션스, 인코포레이티드 | Bcl6 단백질 분해의 조절제 및 관련 사용 방법 |
| WO2023215449A1 (en) | 2022-05-06 | 2023-11-09 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
| EP4519259A1 (en) | 2022-05-06 | 2025-03-12 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
| EP4519260A1 (en) | 2022-05-06 | 2025-03-12 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xdegraders |
| CN115959992A (zh) * | 2022-12-13 | 2023-04-14 | 武汉翱飞科技有限公司 | 一种单分子量聚乙二醇单乙酸的合成方法 |
| TW202527930A (zh) | 2023-11-07 | 2025-07-16 | 美商樹線生物科學公司 | 四氫異喹啉異雙功能ｂｃｌ－ｘｌ降解劑 |
| TW202535872A (zh) | 2023-11-07 | 2025-09-16 | 美商樹線生物科學公司 | 四氫異喹啉異雙功能ｂｃｌ－ｘｌ降解劑 |
| WO2025101575A1 (en) | 2023-11-07 | 2025-05-15 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-x l degraders |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
| EP1143957A3 (en) | 1998-12-16 | 2002-02-27 | Warner-Lambert Company | Treatment of arthritis with mek inhibitors |
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| JP3811775B2 (ja) | 2000-07-19 | 2006-08-23 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | ４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル |
| CN1653059A (zh) | 2002-03-08 | 2005-08-10 | 卫材株式会社 | 用作医药品的大环化合物 |
| KR100984595B1 (ko) | 2002-03-13 | 2010-09-30 | 어레이 바이오파마 인크. | Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체 |
| CA2512000C (en) | 2002-12-26 | 2011-08-09 | Eisai Co., Ltd. | Selective estrogen receptor modulator |
| SI1761528T1 (sl) | 2004-06-11 | 2008-06-30 | Japan Tobacco Inc | 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka |
| WO2007004415A1 (ja) | 2005-07-01 | 2007-01-11 | Murata Manufacturing Co., Ltd. | 多層セラミック基板およびその製造方法ならびに多層セラミック基板作製用複合グリーンシート |
| PE20110220A1 (es) | 2006-08-02 | 2011-04-11 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
| AU2007286808B2 (en) | 2006-08-21 | 2012-12-06 | Genentech, Inc. | Aza-benzofuranyl compounds and methods of use |
| JP5421925B2 (ja) | 2007-12-19 | 2014-02-19 | ジェネンテック， インコーポレイテッド | ５−アニリノイミダゾピリジン及び使用の方法 |
| ES2522346T3 (es) | 2008-08-22 | 2014-11-14 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de CDK |
| NZ593536A (en) | 2008-12-19 | 2013-07-26 | Genentech Inc | Quinoline derivatives and methods of use |
| WO2010080503A1 (en) | 2008-12-19 | 2010-07-15 | Genentech, Inc. | Heterocyclic compounds and methods of use |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| RS56042B1 (sr) | 2010-06-10 | 2017-09-29 | Seragon Pharmaceuticals Inc | Modulatori estrogenih receptora i njihove upotrebe |
| US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| MX368257B (es) | 2011-08-01 | 2019-09-26 | Genentech Inc | Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer. |
| TWI571466B (zh) | 2011-10-14 | 2017-02-21 | 艾伯維有限公司 | 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑 |
| TWI561521B (en) | 2011-10-14 | 2016-12-11 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| KR102668696B1 (ko) | 2012-01-12 | 2024-05-29 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| FR2986002B1 (fr) | 2012-01-24 | 2014-02-21 | Servier Lab | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| ES2671516T3 (es) | 2013-02-19 | 2018-06-06 | Novartis Ag | Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno |
| FR3008975A1 (fr) | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| AP2016009099A0 (en) | 2013-11-01 | 2016-03-31 | Novartis Ag | Aminoheteroaryl benzamides as kinase inhibitors |
| FR3015483B1 (fr) | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| SG11201607339VA (en) | 2014-03-13 | 2016-10-28 | Hoffmann La Roche | Methods and compositions for modulating estrogen receptor mutants |
| RU2738833C9 (ru) | 2014-04-14 | 2022-02-28 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
| CN107207553A (zh) | 2014-12-09 | 2017-09-26 | 艾伯维公司 | Bcl‑xl抑制性化合物和包括其的抗体药物缀合物 |
| CN111620861A (zh) | 2014-12-09 | 2020-09-04 | 艾伯维公司 | 具有低细胞渗透性的bcl-xl抑制性化合物以及包括它的抗体药物缀合物 |
| CN113209306A (zh) | 2014-12-09 | 2021-08-06 | 艾伯维公司 | 具有细胞渗透性的bcl-xl抑制剂的抗体药物缀合物 |
| WO2016105518A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP3270917A4 (en) | 2015-03-18 | 2018-08-08 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| CN109152933B (zh) | 2016-04-21 | 2022-12-02 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
| AU2018258581A1 (en) | 2017-04-28 | 2019-11-07 | Quartz Therapeutics, Inc. | RAF-degrading conjugate compounds |
| ES3041854T3 (en) | 2018-01-22 | 2025-11-17 | Bioventures Llc | Bcl-2 proteins degraders for cancer treatment |
| JP7708662B2 (ja) * | 2018-10-24 | 2025-07-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | コンジュゲート化された化学的分解誘導物質および使用方法 |
| US11547759B2 (en) * | 2019-01-30 | 2023-01-10 | Montelino Therapeutics, Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| CN113660937A (zh) | 2019-02-08 | 2021-11-16 | 佛罗里达大学研究基金公司 | 治疗剂和治疗方法 |
| AU2020310147A1 (en) | 2019-07-10 | 2022-01-06 | Recurium Ip Holdings, Llc | Bcl-2 protein inhibitors |
| AR119493A1 (es) * | 2019-07-29 | 2021-12-22 | Servier Lab | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos |
| AR119494A1 (es) * | 2019-07-29 | 2021-12-22 | Servier Lab | DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS |
-
2022
- 2022-02-01 JP JP2023546439A patent/JP2024505562A/ja active Pending
- 2022-02-01 KR KR1020237029831A patent/KR20230170644A/ko active Pending
- 2022-02-01 US US18/275,379 patent/US20240376094A2/en active Pending
- 2022-02-01 WO PCT/US2022/014790 patent/WO2022169780A1/en not_active Ceased
- 2022-02-01 CA CA3206906A patent/CA3206906A1/en active Pending
- 2022-02-01 CN CN202280024161.7A patent/CN117794929A/zh active Pending
- 2022-02-01 AU AU2022218128A patent/AU2022218128A1/en active Pending
- 2022-02-01 US US18/275,379 patent/US20250179063A2/en active Pending
- 2022-02-01 IL IL304891A patent/IL304891A/en unknown
- 2022-02-01 EP EP22709850.6A patent/EP4288434A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230170644A (ko) | 2023-12-19 |
| AU2022218128A1 (en) | 2023-08-17 |
| US20250179063A2 (en) | 2025-06-05 |
| EP4288434A1 (en) | 2023-12-13 |
| US20240182464A1 (en) | 2024-06-06 |
| IL304891A (en) | 2023-10-01 |
| CN117794929A (zh) | 2024-03-29 |
| WO2022169780A1 (en) | 2022-08-11 |
| CA3206906A1 (en) | 2022-08-11 |
| US20240376094A2 (en) | 2024-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024505562A (ja) | 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法 | |
| US12281127B2 (en) | Pyrido[4,3-d]pyrimidine compounds | |
| ES2963695T3 (es) | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidin-2,6-diona y su uso en el tratamiento de enfermedades dependientes de la proteína con dedos de zinc 2 de la familia ikaros (ikzf2) | |
| KR101671360B1 (ko) | 표적화된 피롤로벤조디아제핀 접합체 | |
| JP7382938B2 (ja) | ジアザインドール化合物 | |
| CN119585286A (zh) | 吡啶并[4,3-d]嘧啶化合物 | |
| CN110305109B (zh) | 新型取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途 | |
| WO2022228543A1 (zh) | 桥环类化合物、其制备方法及其在医药上的应用 | |
| EP4293025B1 (en) | 4-aminoquinazoline compound | |
| CN115368383A (zh) | 稠合含氮杂环类化合物、其制备方法及其在医药上的应用 | |
| WO2024189481A1 (en) | Panras inhibitor antibody-drug conjugates and methods of use thereof | |
| CN118878461A (zh) | Pd-1/pd-l1抑制剂 | |
| CN114174303A (zh) | 作为sting激动剂的大环化合物及其方法和用途 | |
| JP2025100453A (ja) | ピリド［４，３－ｄ］ピリミジン化合物 | |
| US20230416331A1 (en) | Peptide conjugates of peptidic tubulin inhibitors as therapeutics | |
| CN118005655A (zh) | 稠环类化合物、其制备方法及其在医药上的应用 | |
| JP2024539130A (ja) | がんの治療における使用のためのヘテロ環式化合物 | |
| KR20250027282A (ko) | Met bcl-xl 억제제 항체-약물 접합체 및 그의 사용 방법 | |
| HK40111548A (zh) | 选择性bcl-xl protac化合物及使用方法 | |
| CN114685429A (zh) | 碳链环己二酰亚胺类化合物、其制备方法及其在医药上的应用 | |
| RU2857665C2 (ru) | Соединения пиридо[4,3-d]пиримидина | |
| CN114456173B (zh) | 稠环基取代的环己二酰亚胺类衍生物、其制备方法及其在医药上的应用 | |
| WO2025228381A1 (en) | Antibody-drug conjugate and use thereof | |
| WO2025094035A1 (en) | Toll-like receptor agonists and conjugates thereof | |
| WO2025215536A1 (en) | Macrocyclic panras inhibitors for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231110 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250130 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250130 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20251106 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251125 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260219 |